SEC Tracker
Get the app

Protalix BioTherapeutics PLX

Protalix BioTherapeutics reported $21.93 million revenue for Q3 2026.

Protalix BioTherapeutics (PLX) filed a 10-Q with the SEC on Nov 10, 2026, 7:04 am ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $21.93 million for the three months ended Sep 30, 2026
  2. Net income: $3.96 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $22.04 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Protalix BioTherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$21.93M$19.9M+10%
Operating income and margin$4.05M · 18.5%$4.67M · 23.5%−13%, margin −5 pts
Net income$3.96M$3.78M+4.9%
Operating cash flow$3.9M−$10.4M+138%
Cash$22.04M$27.42M−20%

Data on this page was fetched . The filing on SEC.gov is the record.